Immunic, Inc. (NASDAQ:IMUX) CEO Buys $10,800.00 in Stock

Immunic, Inc. (NASDAQ:IMUXGet Rating) CEO Daniel Vitt purchased 8,000 shares of the firm’s stock in a transaction on Tuesday, November 22nd. The shares were acquired at an average cost of $1.35 per share, for a total transaction of $10,800.00. Following the completion of the purchase, the chief executive officer now directly owns 376,877 shares of the company’s stock, valued at approximately $508,783.95. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Immunic Stock Performance

Shares of NASDAQ:IMUX traded up $0.05 during midday trading on Thursday, hitting $1.36. 1,089,820 shares of the stock traded hands, compared to its average volume of 2,007,950. The business’s 50 day moving average is $3.67 and its two-hundred day moving average is $4.19. Immunic, Inc. has a one year low of $1.31 and a one year high of $14.50.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Parkman Healthcare Partners LLC lifted its holdings in Immunic by 11.8% in the 1st quarter. Parkman Healthcare Partners LLC now owns 1,089,251 shares of the company’s stock worth $12,309,000 after buying an additional 115,068 shares during the period. RTW Investments LP lifted its stake in Immunic by 57.7% in the first quarter. RTW Investments LP now owns 2,705,513 shares of the company’s stock worth $30,572,000 after acquiring an additional 990,043 shares during the period. DLD Asset Management LP purchased a new stake in Immunic in the first quarter worth $565,000. Jacobs Levy Equity Management Inc. bought a new stake in Immunic in the third quarter valued at $80,000. Finally, Marshall Wace LLP purchased a new position in Immunic during the 3rd quarter valued at $77,000. Hedge funds and other institutional investors own 59.77% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on IMUX. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Immunic in a research report on Wednesday, September 21st. SVB Leerink downgraded Immunic from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $9.00 to $5.00 in a report on Friday, October 21st. Aegis lowered their target price on Immunic from $40.00 to $35.00 and set a “buy” rating for the company in a research note on Monday, August 8th. StockNews.com began coverage on Immunic in a research report on Wednesday, October 12th. They set a “sell” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $26.00 price target on shares of Immunic in a research note on Monday, September 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Immunic currently has an average rating of “Moderate Buy” and a consensus price target of $23.20.

Immunic Company Profile

(Get Rating)

Immunic, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.

Featured Articles

Insider Buying and Selling by Quarter for Immunic (NASDAQ:IMUX)

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.